|
Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria |
Mar 2021 |
Blood cells, molecules and diseases |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria |
Dec 2020 |
Blood, cells, molecules & diseases |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Future directions in myelodysplastic syndromes/neoplasms and acute myeloid leukaemia classification: from blast counts to biology |
Oct 2024 |
Histopathology |
Myelodysplastic Syndromes (MDS) |
|
Genetic predisposition to MDS: diagnosis and management |
Dec 2019 |
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
|
Genetics of Progression From MDS to Secondary Leukemia |
Jul 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Genetics of Progression From MDS to Secondary Leukemia |
May 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence |
Sep 2019 |
JCO Precision Oncology |
Myelodysplastic Syndromes (MDS) |
|
Genomics of myelodysplastic/myeloproliferative neoplasm |
May 2023 |
Seminars in Diagnostic Pathology |
Myelodysplastic Syndromes (MDS) |
|
Germline DDX41 mutations define a significant entity within adult MDS/AML patients |
Sep 2019 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Germline mutations in MDS/AML predisposition disorders |
Mar 2021 |
Current opinion in hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
